
Opinion|Videos|March 10, 2025
CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC
Experts discuss insights from the CLEAR trial on lenvatinib plus pembrolizumab, focusing on depth of response and clinical outcomes in advanced renal cell carcinoma.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Palbociclib Combo in HR+, HER2+ Metastatic Breast Cancer
2
NCCN Updates Bladder Cancer Guidelines for ctDNA MRD Testing
3
Zanzalintinib/Atezolizumab Misses Survival End Point in Non-MSI-H mCRC Subgroup
4
Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial
5



















































































